Stryker

The consequences of our distinct regulatory set-ups is that sometimes study information that drives indications for use one side of the pond is ignored on the other, despite the fact that it may have significant clinical consequences as seems to be the case with Stryker’s Wingspan Neurovascular Stent.

Stryker Corporation has reported its operating results for the second quarter of 2012 with net sales of $2.1 billion, up 2.9%. Neurotechnology and Spine divisional sales showed greatest percentage growth, although all divisions were up over the equivalent quarter a year ago.

Stryker has undertaken a voluntarily global recall for its Rejuvenate and ABG II modular-neck stems because of post-marketing surveillance data which suggests a potential risk of what it has termed “fretting and corrosion”.

InVivo Therapeutics Holdings Corp., has announced that former Stryker Spine, Inc. executive Robert Housler Jr., will be joining the company as the Vice President of Business Development.

Last week saw the holding of the European Stroke Conference in Lisbon, Portugal, at which event Stryker announced the results of the TREVO 2 clinical trial comparing its Trevo® clot removal device with its current Merci® product.

Stryker’s financial report for Q1 looks pretty rosy as sales and profits climb nicely. Projections are pretty conservative though with anticipated sales growth of 2-5% for the year.

UK MHRA singles out specific combinations of hip/stem for attention, this alert proving the value of the data in England and Wales Joint Registry.

Stryker’s Wingspan Stent is up for FDA panel review on March 23rd. FDA’s Executive Summary, released today doesn’t auger well as results of clinical study don’t seem to support safety and efficacy claims.

Snappy dressers these new powertools from Stryker, offering a range of “enhancements” including quieter operation, better battery life and heightened torque.

MacMillan leaves Stryker with immediate effect for personal reasons.

AAOS is on right now in San Francisco. Here are Stryker’s “showcased” offerings from the event.

Stryker Corporation has announced that it’s Biotech division has reached a settlement with the U.S. Attorney’s Office for the District of Massachusetts, agreeing to pay a non-tax deductible fine of $15 million for one misdemeanour. Thirteen other felony charges will be dismissed.

Despite a generally gloomy outlook Stryker financials and predictions for 2012 look strong from preliminary report.

Clinical concerns about Hip Resurfacing will negatively affect growth in the Hip segment, according to a new Millennium Research Group report.

Kensey Nash Corporation has been awarded a two-year, $1.9 million grant to investigate the use of a bioadhesive surgical mesh for applications in tendon repair procedures.

Stryker has announced its intention to implement focused workforce reductions of approximately 5% of its global workforce and other restructuring activities that are anticipated to reduce annual pre-tax operating costs by over $100 million beginning in 2013.